Inrebic

Chemical Namefedratinib
Dosage FormCapsule (oral; 100 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyImpact
Approval Year2019

Indication

  • Inrebic is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Last updated on 11/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Inrebic (fedratinib) Prescribing Information 2019Celgene